Russia's Biocad completes registration of generic of glatiramer acetate

14 November 2016

Russian drugmaker Biocad has announced that it has successfully completed registration of a generic of glatiramer acetate, a drug for the treatment of multiple sclerosis, reports The Pharma Letter’s local correspondent.

According to the company, prices for its drug will be 30% less than those for the original drug, trade name Copaxone, which is produced by Israel’s Teva Pharmaceutical Industries (NYSE: TEVA).

Development of glatiramer acetate began in 2012. The drug became the subject of a two-year Phase III clinical study, which proved it equivalence to the original drug, in terms of all indicators of efficacy and safety. The volume of investments in conducting clinical studies amounted to 400 million roubles ($6.1 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK